AKBA News and Press, Akebia Therapeutics Inc. From 08/02/23

2023-08-02 19:00:48 ET Summary Akebia Therapeutics plans to resubmit its FDA application for kidney disease drug vadadustat by Q3 2023, following initial rejection over safety concerns. Despite a decrease in revenues and a net loss in Q1 2023, Akebia's stock has seen significant g...

2023-08-02 16:34:09 ET Summary Akebia is cash poor with a lot of debt. Q2 revenues will likely miss estimates. Pipeline is weak but company has a path to a second U.S. drug. Post-earnings catalysts may spark rallies. Akebia Therapeutics ( AKBA ) is a small ($~340...

2023-07-25 10:18:59 ET Gainers: Bullfrog AI ( BFRG ) +35% . Carmell Therapeutics ( CTCX ) +32% . Kiniksa Pharmaceuticals ( KNSA ) +21% . Galecto ( GLTO ) +18% . Akebia Therapeutics ( AKBA ) +16% . Losers: NeuroOne Med...

Akebia Therapeutics to Present at the H.C. Wainwright Kidney Conference PR Newswire CAMBRIDGE, Mass. , July 19, 2023 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted ...

2023-07-18 11:14:56 ET Akebia Therapeutics ( NASDAQ: AKBA ) said it plans to resubmit its market application to the FDA by the end of Q3 for its kidney disease drug vadadustat, which the agency declined to approve last year. Akebia is seeking to have the drug approved to tre...

Akebia Therapeutics Completed Type A Meeting with the FDA and Expects to Resubmit Vadadustat NDA in Third Quarter 2023 PR Newswire CAMBRIDGE, Mass. , July 18, 2023 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutic...

2023-07-10 12:16:34 ET There are so many new traders and investors entering the stock market today. But if you’re brand new, you might not have a lot of money to invest or don’t want to risk a whole lot while you’re learning how to trade. So this begs the question, ...

2023-07-06 06:07:40 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Investors seeking high-growth opportunities often turn their attention to penny stocks , which may have the potential to deliver substantial returns. The three potential high return penny s...

Akebia Therapeutics Announces Positive Top-Line Results of Phase 4 IMPACT Study of Auryxia® (ferric citrate) for In-Center and Home Dialysis Patients PR Newswire CAMBRIDGE, Mass. , June 29, 2023 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: ...

2023-06-20 08:30:00 ET BranchOut Food ( BOF ) +36% Secures Major Supplier Contract with Walmart. DICE Therapeutics ( DICE ) +38% stock movers today: Nikola, Arcellx, DICE Therapeutics, Beam Global and more. VCI Global  ( VCIG ) +-6% To Distribute...